Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.
暂无分享,去创建一个
R. Collins | D. Porter | R. Mick | S. Giralt | A. Leahey | J. Antin | N. Kernan | P. Parker | J. Casper | W. Drobyski | W. Drobyski | M. Flowers | R. King | S. Giralt | B. Bate-Boyle | C. Hardy | Ann Leahey | David L Porter | Robert H. Collins | James T. Casper | R. King | Christine Hardy | Pablo Parker | Rosemarie Mick | B. Bate-Boyle
[1] D. Neuberg,et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. , 1998, Blood.
[2] J. Goldman,et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors , 1998, Bone Marrow Transplantation.
[3] S. Singhal,et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy , 1997, Bone Marrow Transplantation.
[4] Robert H. Collins,et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Porter,et al. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. , 1996, Bone marrow transplantation.
[6] A. Nagler,et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. , 1996, Blood.
[7] H. Kantarjian,et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1995, Blood.
[8] M. Hessner,et al. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. , 1995, Blood.
[9] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[10] S. Mackinnon,et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.
[11] J. Radich,et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. , 1995, Blood.
[12] J. Goldman,et al. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. , 1994, Bone marrow transplantation.
[13] J. Goldman,et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. , 1994, Blood.
[14] D. Porter,et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. , 1994, The New England journal of medicine.
[15] H. Heimpel,et al. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. , 1993, Transplantation.
[16] B. Chapuis,et al. Adoptive immunotherapy for recurrent CML after BMT. , 1993, Bone marrow transplantation.
[17] T. Smetsers,et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Szer,et al. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. , 1993, Bone marrow transplantation.
[19] J. Radich,et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Gratwohl,et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A REPORT BY THE EBMT LEUKAEMIA WORKING PARTY , 1991, British journal of haematology.
[21] J. Ritz,et al. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. , 1991, Blood.
[22] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[23] V. Barnett,et al. Applied Linear Statistical Models , 1975 .
[24] D. Cox,et al. The analysis of binary data , 1971 .
[25] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[26] S. Mackinnon,et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. , 1999, Blood.
[27] M. Horowitz,et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. , 1993, Blood.
[28] M. Horowitz,et al. Second HLA-identical sibling transplants for leukemia recurrence. , 1992, Bone marrow transplantation.
[29] D. Ginsburg,et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. , 1992, Blood.
[30] W. Wilmanns,et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.